emavusertib
emavusertib: developed by 1 company · 7 clinical trials tracked.
emavusertib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could emavusertib → CRIS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| CURIS INC (CRIS) Chronic Lymphocytic Leukemia; Relapsed Hematologic Malignanc… | Phase 2 |
| CURIS INC (CRIS) Chronic Lymphocytic Leukemia; Relapsed Hematologic Malignanc… | Phase 1 |
Clinical Trials (7)
A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Primary endpoint: Cohort 1: Undetectable Measurable Residual Disease (uMRD) Rate
Phase I Trial of Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Primary endpoint: To determine the safety of emavusertib in combination with gemcitabine, cisplatin, and durvalumab in patients with BTC as measured by incidences and types of adverse events
Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer
Primary endpoint: Dose limiting toxicities (DLT)
Phase 1 Trial of CA-4948 in Combination With Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer
Primary endpoint: Dose limiting toxicities (DLTs)
A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
Primary endpoint: Dose limiting toxicity rate
A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Primary endpoint: Determine Maximum Tolerated Dose (MTD) of emavusertib (CA-4948) monotherapy (Phase 1)
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Primary endpoint: Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)
Frequently asked questions
Who is developing emavusertib?
emavusertib is being developed by CURIS INC.
How many clinical trials involve emavusertib?
BioSniper tracks 7 clinical trials involving emavusertib.